lenalidomide zentiva 10 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 10 mg
lenalidomide zentiva 15 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 15 mg
lenalidomide zentiva 25 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 25 mg
lenalidomide zentiva 5 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 5 mg
bendamustine medac 2,5 mg/ml pulveris infūziju šķīduma koncentrāta pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bendamustīna hidrohlorīds - pulveris infūziju šķīduma koncentrāta pagatavošanai - 2,5 mg/ml
lenalidomide stada 5 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 5 mg
lenalidomide stada 15 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 15 mg
lenalidomide accord
accord healthcare s.l.u. - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide vienojoties kopā ar deksametazona ir indicēts, lai ārstētu multiplā mieloma pieaugušo pacientiem, kuri ir saņēmuši vismaz vienu pirms terapijas. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
ultomiris
alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
lenalidomide norameda 25 mg cietās kapsulas
norameda uab, lithuania - lenalidomīds - kapsula, cietā - 25 mg